- Home
- IMMX vs HHS Comparison
IMMX vs HHS Comparison
Compare IMMX & HHS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMMX
- HHS
- Stock Information
- Founded
- IMMX 2014
- HHS 1923
- Country
- IMMX United States
- HHS United States
- Employees
- IMMX N/A
- HHS N/A
- Industry
- IMMX Medicinal Chemicals and Botanical Products
- HHS Advertising
- Sector
- IMMX Health Care
- HHS Consumer Discretionary
- Exchange
- IMMX Nasdaq
- HHS Nasdaq
- Market Cap
- IMMX 61.1M
- HHS 39.4M
- IPO Year
- IMMX 2021
- HHS N/A
- Fundamental
- Price
- IMMX $2.19
- HHS $5.35
- Analyst Decision
- IMMX Strong Buy
- HHS
- Analyst Count
- IMMX 1
- HHS 0
- Target Price
- IMMX $7.00
- HHS N/A
- AVG Volume (30 Days)
- IMMX 223.0K
- HHS 21.5K
- Earning Date
- IMMX 11-12-2024
- HHS 11-14-2024
- Dividend Yield
- IMMX N/A
- HHS N/A
- EPS Growth
- IMMX N/A
- HHS N/A
- EPS
- IMMX N/A
- HHS N/A
- Revenue
- IMMX N/A
- HHS $187,604,000.00
- Revenue This Year
- IMMX N/A
- HHS N/A
- Revenue Next Year
- IMMX $200.00
- HHS $4.05
- P/E Ratio
- IMMX N/A
- HHS N/A
- Revenue Growth
- IMMX N/A
- HHS N/A
- 52 Week Low
- IMMX $1.26
- HHS $5.25
- 52 Week High
- IMMX $7.07
- HHS $8.87
- Technical
- Relative Strength Index (RSI)
- IMMX 53.40
- HHS 35.21
- Support Level
- IMMX $2.03
- HHS $5.25
- Resistance Level
- IMMX $2.30
- HHS $5.59
- Average True Range (ATR)
- IMMX 0.28
- HHS 0.21
- MACD
- IMMX -0.02
- HHS 0.02
- Stochastic Oscillator
- IMMX 43.06
- HHS 18.48
About IMMX Immix Biopharma Inc.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.
About HHS Harte-Hanks Inc.
Harte-Hanks Inc is a customer experience company. The Company operates three business segments: Marketing Services; Customer Care; and Fulfillment & Logistics Services. The company has a geographic presence in the United States and Other countries. The majority of the revenue is earned from the United States.